Clinical trials: Cell Transplantation
Chronic Gastrointestinal Graft vs Host Disease
Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
- Trial name
- NCT01925950
- Testing
- orBec
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Soligenix
GVHD, Hematologic Neoplasms
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host…
- Trial name
- NCT03680092
- Testing
- Cyclophosphamide, abatacept, Methotrexate
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Dimitrios Tzachanis, MD PhD
Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
This is a single-arm, multi-center Phase II trial using IL-15 super-agonist complex (N-803 formerly known as Alt-803) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for acute myelogenous leukemia (AML) and…
- Trial name
- NCT02989844
- Testing
- N-803
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Heart Failure, Congestive
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
Heart failure is a condition in which the heart is unable to pump enough blood to the body's other organs. A heart transplant may be necessary for some individuals with end-stage heart failure.
- Trial name
- NCT00383630
- Testing
- Intramyocardial injection of bone marrow mononuclear cells, Intramyocardial injection of CD34+ selected bone marrow mononuclear cells, LVAD alone
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Complete DiGeorge Anomaly, DiGeorge Syndrome
Thymus Transplantation Safety-Efficacy
Complete DiGeorge anomaly (cDGA) is a disorder in which there is no thymus function. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection.
- Conditions
- Complete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- NCT01220531
- Testing
- Cultured Thymus Tissue
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL)
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors and post-transplantation cyclophosphamide…
- Conditions
- Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma
- Trial name
- NCT02793544
- Testing
- Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Graft vs. Host Disease
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
To determine whether treatment with ustekinumab will alter the ratio of T Regulatory Cell (Treg)/total cluster of differentiation 4 (CD4)+ cells in peripheral blood at day 30 post-hematopoietic cell transplantation (HCT).
- Trial name
- Ustekinumab (NCT01713400)
- Testing
- Ustekinumab, Tacrolimus (TAC), Sirolimus
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Myelodysplastic Syndrome
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
This is a pilot study which will be done in a small number of patients. The purpose of this study is to test the safety and benefit of giving a type of chemotherapy - cyclophosphamide - after the transplant to prevent graft…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02360111
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
This randomized phase II trial studies the safety and how well multi-peptide cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) vaccine works in reducing CMV complications in patients previously infected with CMV and are…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia
- Trial name
- NCT02506933
- Testing
- Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- City of Hope Medical Center
Immunodeficiency Syndrome, Non-Cancer Diagnosis
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders
This phase II trial studies fludarabine phosphate and total-body irradiation with or without alemtuzumab followed by donor stem cell transplant to see how well it works in treating patients with immunodeficiency or other…
- Trial name
- NCT00553098
- Testing
- Alemtuzumab, Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
This phase I trial studies the side effects and best dose of iodine I 131monoclonal antibody BC8 when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, and donor bone marrow transplant, and to…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, CD45-Positive Neoplastic Cells Present
- Trial name
- NCT00589316
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myeloid, Leukemia
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Acute myeloid leukemia (AML) is a cancer of the bone marrow that mostly affects older adults. Even with the best chemotherapy, two-year disease-free survival is achieved in a minority of patients.
- Conditions
- Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
- Trial name
- NCT00568633
- Testing
- Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP)
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Stanford University
Hematologic Diseases
Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
The purpose of this research study is to measure the effects of using a mobile phone app (Roadmap 2.0) on the health-related quality of life of caregivers and patients undergoing allogeneic/autologous hematopoietic cell…
- Trial name
- NCT04094844
- Testing
- Wearable activity sensor, Roadmap 2.0 information system, Survey administration
- Where
- 2 sites in United States
- Volunteers
- 372 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
Background: Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells) have been used with varying degrees of success as an immune therapy for blood-system cancers (leukemias, myelodysplastic…
- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Hodgkins Lymphoma
- Trial name
- NCT01326728
- Testing
- Allogeneic stem cell transplant
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Severe Combined Immunodeficiency
SCID Bu/Flu/ATG Study With T Cell Depletion
This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with a diagnosis of Severe Combined Immune Deficiency (SCID) who do not have an HLA-matched sibling donor.
- Trial name
- NCT02127892
- Testing
- unrelated BM with T cell depletion, unrelated cord blood, haplo BM with T cell depletion
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Neena Kapoor, M.D.
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
This phase II trial investigates side effects and how well donor stem cell transplant after chemotherapy works in treating pediatric and adolescent-young adults with high-risk solid tumor that has come back (recurrent) or does…
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor
- Trial name
- NCT04530487
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Mycoses, Sezary Syndrome
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of…
- Conditions
- Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marrow Transplant Failure
- Trial name
- NCT00896493
- Testing
- anti-thymocyte globulin, cyclosporine, Lymphoid radiation
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Stanford University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This phase II trial studies how well giving fludarabine phosphate, melphalan, and low-dose total-body irradiation (TBI) followed by donor peripheral blood stem cell transplant (PBSCT) works in treating patients with hematologic…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01529827
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
This is a single-arm, Phase II study of crenolanib as maintenance in AML patients with FLT3 mutations who have achieved complete remission (CR) after allogeneic stem cell transplantation.
- Trial name
- NCT02400255
- Testing
- Crenolanib besylate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Hematopoietic/Lymphoid Cancer
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
This phase II trial studies how well total-body irradiation, donor lymphocyte infusion, and cyclophosphamide before donor stem cell transplant works in treating patients with high-risk hematologic malignancies.
- Trial name
- NCT01982682
- Testing
- Total-Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.